African Trypanosomiasis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

African trypanosomiasis, also referred to as human African trypanosomiasis (HAT) or sleeping sickness, is a disease caused by one of two protozoa, Trypanosoma brucei, transmitted by the tsetse fly in sub-Saharan Africa. This illness falls under the category of neglected tropical diseases and poses a significant threat, as it is often fatal if left untreated. Trypanosoma brucei is typically transmitted to humans through the bite of an infected tsetse fly. Once the tsetse fly acquires the trypanosomes, they undergo multiplication and develop into epimastigotes. Humans become infected following a tsetse fly bite, after which the injected parasites rapidly proliferate in the bloodstream and lymphatic system. Ultimately, the parasite infiltrates the central nervous system (CNS), leading to neurological and behavioral symptoms. In some cases, individuals may experience a severe hypersensitivity reaction to the parasite, resulting in itching, swelling, and edema. To detect HAT caused by Trypanosoma brucei gambiense, the card agglutination trypanosoma test (CATT) can be utilized. Management in the early stages necessitates the treatment of symptoms like fever and malaise. Close monitoring of the CNS status is essential, and in severe cases, patients may require intubation and mechanical ventilation to maintain a clear airway. HAT caused by Trypanosoma brucei gambiense is treated differently depending on the disease stage. In the first stage, treatment involves the use of pentamidine. When patients progress to CNS symptoms, they require eflornithine and nifurtimox. If there is no response to these treatments, healthcare providers may consider melarsoprol. For HAT caused by Trypanosoma brucei rhodesiense, the treatment approach varies. In the initial stage, suramin is administered, while in the second stage, melarsoprol is the preferred treatment. If the infection is identified and treated during the early stage, most patients can recover. However, when the patient presents with stage 2 disease, CNS involvement typically leads to a fatal outcome. Presently, the cure rate with the drug melarsoprol exceeds 90%.

Thelansis’s “African Trypanosomiasis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential African Trypanosomiasis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of African Trypanosomiasis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

African Trypanosomiasis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: African Trypanosomiasis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033